| US266710A (en) | | 1882-10-31 | | Fastening for pocket-books |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (en) | 1989-04-28 | 1991-08-30 | Transgene Sa | NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US6737056B1 (en)* | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| AR036993A1 (en) | 2001-04-02 | 2004-10-20 | Wyeth Corp | USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS |
| JP4249013B2 (en) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Substance with specificity for PD-1 |
| US7488802B2 (en) | 2002-12-23 | 2009-02-10 | Wyeth | Antibodies against PD-1 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| PL1729795T3 (en) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Albumin fusion proteins |
| CA3151350A1 (en) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2009026472A1 (en) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
| CA2742926A1 (en) | 2007-11-28 | 2009-06-04 | Universite De Montreal | Pd-1 modulation and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CN102892786B (en) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1 antibody |
| AR083044A1 (en)* | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
| ES2609439T3 (en) | 2010-12-31 | 2017-04-20 | Bioatla Llc | Rapid humanization of antibodies |
| EP3939613A1 (en) | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| WO2014179664A2 (en) | 2013-05-02 | 2014-11-06 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
| CN104250302B (en) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
| US10077305B2 (en) | 2013-09-10 | 2018-09-18 | Medimmune Limited | Antibodies against PD-1 and uses thereof |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody Molecules of PD-1 and Their Uses |
| CN105330740B (en) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | Anti- PD-1 antibody and its application |
| CA2957258C (en) | 2014-08-05 | 2023-11-07 | MabQuest SA | Immunological reagents |
| TWI595006B (en)* | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-PD-1 antibodies and methods of using same |
| EP3237446B1 (en) | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| HK1254803A1 (en) | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | Novel pd-1 immune modulating agents |
| CN106699888B (en) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | PD-1 antibody and preparation method and application thereof |
| JP6843868B2 (en) | 2015-09-29 | 2021-03-17 | セルジーン コーポレイション | PD-1 binding protein and its usage |
| MY190297A (en) | 2015-10-02 | 2022-04-12 | Hoffmann La Roche | Anti-pd1 antibodies and methods of use |
| US11034765B2 (en) | 2015-10-02 | 2021-06-15 | Symphogen A/S | Anti-PD-1 antibodies and compositions |
| WO2017079080A1 (en) | 2015-11-02 | 2017-05-11 | The Johns Hopkins University | Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway |
| CN106699889A (en) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | PD-1 resisting antibody and treatment application thereof |
| JP2019509759A (en) | 2016-01-14 | 2019-04-11 | ビーピーエス バイオサイエンス、インク．Ｂｐｓ Ｂｉｏｓｃｉｅｎｃｅ， Ｉｎｃ． | Anti-PD-1 antibody and use thereof |
| US11299751B2 (en)* | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CN107474136B (en) | 2016-06-08 | 2023-03-07 | 上海交通大学医学院 | Antibody heavy chain constant region sequences that enhance the activity of agonistic antibodies |
| RU2656181C1 (en) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Anti-pd-1 antibodies, method for their production, and method of application |
| KR102266788B1 (en) | 2016-09-14 | 2021-06-22 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Antibodies specifically binding to PD-1 and functional fragments thereof |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | Methods of treating vitiligo using pd-1 binding proteins |
| CA3036701A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
| CN114456269A (en) | 2016-09-21 | 2022-05-10 | 基石药业（苏州）有限公司 | Novel PD-1 monoclonal antibody |
| PL3515938T3 (en) | 2016-09-21 | 2025-06-09 | Cstone Pharmaceuticals | Monoclonal antibodies to programmed death 1 (pd-1) |
| SG10201913306WA (en) | 2016-11-01 | 2020-02-27 | Anaptysbio Inc | Antibodies directed against programmed death- 1 (pd-1) |
| WO2018085358A1 (en) | 2016-11-02 | 2018-05-11 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
| CN110214153B (en) | 2016-11-18 | 2024-03-29 | 法国施维雅药厂 | anti-PD-1 antibodies and compositions |
| CN106519034B (en) | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | anti-PD-1 antibodies and uses thereof |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| KR20190104411A (en) | 2017-01-18 | 2019-09-09 | 제넨테크, 인크. | Idiotype Antibodies to Anti-PD-L1 Antibodies and Uses thereof |
| MX2019007848A (en) | 2017-01-20 | 2019-09-09 | Tayu Huaxia Biotech Medical Group Co Ltd | Anti-pd-1 antibodies and uses thereof. |
| CN108341871A (en) | 2017-01-24 | 2018-07-31 | 三生国健药业（上海）股份有限公司 | Anti- PD-1 monoclonal antibodies and its preparation method and application |
| KR20190141658A (en) | 2017-03-29 | 2019-12-24 | 셀진 코포레이션 | Formulations Comprising PD-1 Binding Proteins and Methods for Making the Same |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| WO2018223923A1 (en) | 2017-06-05 | 2018-12-13 | 江苏恒瑞医药股份有限公司 | Use of pd-1 antibody combined with vegf ligand or vegf receptor inhibitor in preparing drug for treating tumor |
| UA128035C2 (en) | 2017-06-05 | 2024-03-20 | Янссен Байотек, Інк. | AN ANTIBODY THAT SPECIFICALLY BINDS PD-1 AND METHOD OF ITS USE |
| MX2020001328A (en) | 2017-08-03 | 2020-03-20 | Amgen Inc | INTERLEUKIN 21 MUTEINS AND TREATMENT METHODS. |
| AU2019207895A1 (en) | 2018-01-12 | 2020-06-18 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
| TWI708787B (en) | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1 agonist antibodies and uses thereof |
| IL277095B1 (en) | 2018-03-07 | 2025-06-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| WO2019179390A1 (en) | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/egfr antibody molecules |
| WO2019179391A1 (en) | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
| WO2019179421A1 (en) | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
| WO2019179434A1 (en) | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/cd47 antibody molecules |
| EP3768724A4 (en) | 2018-03-20 | 2022-04-13 | Wuxi Biologics Ireland Limited. | NOVEL ANTI-PD-1 ANTIBODIES |
| EP3794039A4 (en) | 2018-05-17 | 2022-05-04 | Nanjing Leads Biolabs Co., Ltd. | PD-1 BINDING ANTIBODIES AND USES THEREOF |
| US12258407B2 (en) | 2018-07-19 | 2025-03-25 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-PD-1 antibodies, dosages and uses thereof |
| CN110734493B (en)* | 2018-07-20 | 2021-12-17 | 厦门大学 | anti-PD-1 antibodies and uses thereof |
| EP3876978A4 (en) | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
| EP3892299A4 (en) | 2018-12-07 | 2022-11-30 | ONO Pharmaceutical Co., Ltd. | IMMUNOSUPPRESSANT |
| TWI862565B (en) | 2019-04-04 | 2024-11-21 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
| CN110577599A (en) | 2019-05-13 | 2019-12-17 | 深圳市润科生物科技有限公司 | humanized anti-programmed death-1 (PD-1) antibody and application thereof |
| JP7490679B2 (en) | 2019-06-05 | 2024-05-27 | アナプティスバイオ インコーポレイティッド | PD-1 agonists and methods of using same |
| KR20220042257A (en) | 2019-07-12 | 2022-04-04 | 더 존스 홉킨스 유니버시티 | Compositions and methods for treating cerebral vasospasm |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| US20210206856A1 (en) | 2019-08-19 | 2021-07-08 | Pandion Therapeutics, Inc. | Targeted immunotolerance with a pd-1 agonist |
| EP4076385A1 (en) | 2019-12-20 | 2022-10-26 | Formycon AG | Formulations of anti-pd1 antibodies |
| CN113004408B (en) | 2019-12-20 | 2022-07-01 | 广东菲鹏制药股份有限公司 | Anti-human apoptosis factor-1 monoclonal antibody |
| CN110787292B (en) | 2020-01-06 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | Programmed cell death receptor 1 antibody preparation and application thereof |
| KR20210097882A (en) | 2020-01-30 | 2021-08-10 | 삼성바이오에피스 주식회사 | Stable anti-PD-1 antibody pharmaceutical formulations |
| CN113456582B (en) | 2020-03-30 | 2024-06-14 | 鲁南制药集团股份有限公司 | Liquid preparation of recombinant humanized anti-PD-1 monoclonal antibody |
| CN115697405A (en) | 2020-05-25 | 2023-02-03 | 公益财团法人神户医疗产业都市推进机构 | Pharmaceutical composition comprising PD-1 agonist for treating or preventing Th2 mediated diseases |
| MX2022014974A (en) | 2020-05-26 | 2023-01-11 | Boehringer Ingelheim Int | Anti-pd-1 antibodies. |
| CN113797330A (en) | 2020-06-11 | 2021-12-17 | 三生国健药业（上海）股份有限公司 | anti-PD-1 monoclonal antibody liquid preparation |
| US20230272106A1 (en) | 2020-06-19 | 2023-08-31 | Sinocelltech Ltd | Stable formulation for recombinant anti-pd-1 monoclonal antibody |
| CN111956799A (en) | 2020-09-18 | 2020-11-20 | 生物抗素公司 | Application of anti-PD-1 antibody and/or PD-L1 antibody in preparation of medicine for treating Parkinson's disease |